ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

Insulin-resistance-fighting drug continues to protect against type 2 diabetes

  [ 48 votes ]   [ Discuss This Article ] • June 17, 2003

USC study finds pioglitazone deters diabetes in women at high risk

NEW ORLEANS (June 17)- Administering a commonly available drug to lower insulin resistance in women who are at high risk for type 2 diabetes appears to prevent onset of the disease, according to a study by researchers at the Keck School of Medicine of the Univesity of Southern California presented at the American Diabetes Association's 63rd Annual Scientific Sessions today.

The Pioglitazone in Prevention of Diabetes (PIPOD) study tested whether piglitazone could continue protecting women from diabetes just as troglitazone had done in the researchers' prior study, TRIPOD. Both drugs appear to reduce the demands placed on beta cells, which must secrete large amounts of insulin to regulate glucose when patients become insulin resistant. The researchers switched to prescribing pioglitazone, known by the brand name Actos, after the Food and Drug Administration recalled troglitazone in 2000.

Although gestational diabetes usually disappears after childbirth, patients commonly remain resistant to their own insulin, and 30 to 50 percent of them develop type 2 diabetes within a few years after pregnancy, says Anny H. Xiang, Ph.D., assistant professor of research in preventive medicine at the Keck School of Medicine and study presenter.

For this study, Xiang and colleagues enrolled 117 young Latinas with recent gestational diabetes who had participated in their prior TRIPOD study. TRIPOD had found that women taking troglitazone were 55 percent less likely to develop diabetes than women who got a placebo, and their glucose levels remained stable for nearly five years. All 117 women in PIPOD were given pioglitazone.

Researchers now report that out of 76 PIPOD participants who started PIPOD without diabetes and who had an oral glucose tolerance test after being on pioglitazone for a year, only one woman (about 1 percent) developed diabetes. And of the 26 women who started PIPOD with mild diabetes, only nine still had a diabetic glucose level after a year.

The 46 women in PIPOD who had taken troglitazone during TRIPOD saw their blood sugar and insulin levels reduced by about the same amount during the first year of both studies. And the 56 women on placebo during the first study saw their glucose and insulin levels fall significantly during PIPOD compared to their levels in the first year of TRIPOD.

"So, the protection from diabetes that we saw in TRIPOD persisted during the first year of PIPOD," says Thomas A. Buchanan, M.D., professor of medicine, obstetrics and gynecology and physiology and biophysics at the Keck School and a study author. "And starting pioglitazone treatment in women who were on placebo during TRIPOD lowered blood sugar and insulin levels appears to be protecting them against diabetes as well."

Here is how it works: Beta cells, located in the pancreas, produce insulin in response to glucose, and they are the primary regulators of blood sugar. When they are overloaded over time, through the condition called insulin resistance, they begin to wear out. Their failure leads to diabetes.

Pioglitazone reduces chronic insulin resistance's demands on beta cells. It does this by increasing the body's sensitivity to insulin. With lower demands, beta cells do not fail as fast, and, in some patients, do not fail at all. When beta cells do not fail, patients do not get diabetes. Researchers will continue following the women for three more years to better understand protective effects.

The next question: Why do some people's beta cells fail under a high workload, while other people's beta cells do just fine?

Xiang, Buchanan and colleagues suspect genes are to blame. They are looking at families of women with gestational diabetes to see if their siblings have the same basic problem with their beta cells. They seek to identify genes that could contribute to diabetes risk among Mexican-Americans.

Collaborator Richard Watanabe, Ph.D., assistant professor of preventive medicine at the Keck School, reported at the meeting that the level of beta-cell function tends to run in families, as does (but to a lesser extent) the tendency to become insulin resistant. The finding underpins a large, family-based study to find genes predisposing Latinos to beta-cell problems leading to diabetes.

For abstracts and information about the meeting, go to

Anny H. Xiang, Ruth K. Peters, Siri L. Kjos, Jose Goico, Auro Marroquin, Cesar Ochoa, Sylvia Tan and Thomas A. Buchanan, "Continued Protection from Diabetes during Treatment of the TRIPOD Cohort with Pioglitazone," American Diabetes Association's 63rd Annual Scientific Sessions, Oral Presentation 322 in Treatment of Insulin Resistance session, 8 a.m. - 10 a.m., June 17, 2003.

Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ FibroSleep™ Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
Safely Burn Away Body Fat Safely Burn Away Body Fat
When a Negative is Positive - Goodnighties Recovery Sleepwear When a Negative is Positive - Goodnighties Recovery Sleepwear
Live Without Anxiety or Stress Live Without Anxiety or Stress
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map